You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFenoldopam
Accession NumberDB00800  (APRD00969)
TypeSmall Molecule
GroupsApproved
DescriptionA dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. [PubChem]
Structure
Thumb
Synonyms
Fenoldopam
Fénoldopam
Fenoldopam
Fenoldopamum
External Identifiers
  • SKF 82526
  • SKF 82526-J
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Corlopaminjection, solution10 mg/mLintravenousHospira, Inc.1997-09-23Not applicableUs
Corlopaminjection, solution10 mg/mLintravenousHospira, Inc.1997-09-23Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fenoldopam mesylate
67227-57-0
Thumb
  • InChI Key: CVKUMNRCIJMVAR-UHFFFAOYSA-N
  • Monoisotopic Mass: 401.0699862
  • Average Mass: 401.86
DBSALT000945
Categories
UNIIINU8H2KAWG
CAS number67227-56-9
WeightAverage: 305.756
Monoisotopic: 305.08187109
Chemical FormulaC16H16ClNO3
InChI KeyInChIKey=TVURRHSHRRELCG-UHFFFAOYSA-N
InChI
InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2
IUPAC Name
6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
SMILES
OC1=CC=C(C=C1)C1CNCCC2=C(Cl)C(O)=C(O)C=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassNot Available
Direct ParentBenzazepines
Alternative Parents
Substituents
  • Benzazepine
  • Chlorocatechol
  • 3-chlorocatechol
  • 2-halophenol
  • 3-halophenol
  • 1,2-diphenol
  • Aralkylamine
  • Phenol
  • Azepine
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Azacycle
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function.
PharmacodynamicsFenoldopam is an agonist at D1-like dopamine receptors, binds to α2-adrenoceptors, increasing renal blood flow.
Mechanism of actionFenoldopam is a rapid-acting vasodilator. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and β-adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam is a racemic mixture with the R-isomer responsible for the biological activity. The R-isomer has approximately 250-fold higher affinity for D1-like receptors than does the S-isomer. In non-clinical studies, fenoldopam had no agonist effect on presynaptic D2-like dopamine receptors, or α or β -adrenoceptors, nor did it affect angiotensin-converting enzyme activity. Fenoldopam may increase norepinephrine plasma concentration.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Elimination is largely by conjugation, without participation of cytochrome P-450 enzymes. Methylation, glucuronidation, and sulfation are the main routes of conjugation.

Route of eliminationRadiolabeled studies show that about 90% of infused fenoldopam is eliminated in urine, 10% in feces. Elimination is largely by conjugation, without participation of cytochrome P-450 enzymes. Only 4% of the administered dose is excreted unchanged.
Half lifeThe elimination half-life is about 5 minutes in mild to moderate hypertensives, with little difference between the R (active) and S isomers.
ClearanceNot Available
ToxicityThe most likely reaction of overdose would be excessive hypotension which should be treated with drug discontinuation and appropriate supportive measures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.7784
Caco-2 permeable-0.5345
P-glycoprotein substrateSubstrate0.8329
P-glycoprotein inhibitor INon-inhibitor0.9142
P-glycoprotein inhibitor IINon-inhibitor0.8567
Renal organic cation transporterNon-inhibitor0.6062
CYP450 2C9 substrateNon-substrate0.8216
CYP450 2D6 substrateNon-substrate0.7124
CYP450 3A4 substrateNon-substrate0.5301
CYP450 1A2 substrateNon-inhibitor0.713
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8316
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7436
Ames testNon AMES toxic0.7166
CarcinogenicityNon-carcinogens0.9006
BiodegradationNot ready biodegradable0.9935
Rat acute toxicity2.7788 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6864
hERG inhibition (predictor II)Inhibitor0.8833
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • Bedford laboratories
  • Pharmaforce inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous10 mg/mL
Prices
Unit descriptionCostUnit
Fenoldopam 10 mg/ml ampule213.75USD ml
Corlopam 10 mg/ml ampul81.9USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility4000 mg/LNot Available
logP2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.272 mg/mLALOGPS
logP2.39ALOGPS
logP1.92ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)8.12ChemAxon
pKa (Strongest Basic)10.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.68 m3·mol-1ChemAxon
Polarizability30.71 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US4197297
General ReferencesNot Available
External Links
ATC CodesC01CA19
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (239 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Fenoldopam.
AcebutololFenoldopam may increase the hypotensive activities of Acebutolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Fenoldopam.
AliskirenFenoldopam may increase the hypotensive activities of Aliskiren.
AlprenololFenoldopam may increase the hypotensive activities of Alprenolol.
AmbrisentanFenoldopam may increase the hypotensive activities of Ambrisentan.
AmifostineFenoldopam may increase the hypotensive activities of Amifostine.
AmlodipineAmlodipine may increase the hypotensive activities of Fenoldopam.
AtenololAtenolol may increase the hypotensive activities of Fenoldopam.
BenazeprilBenazepril may increase the hypotensive activities of Fenoldopam.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Fenoldopam.
BenmoxinBenmoxin may increase the hypotensive activities of Fenoldopam.
BepridilFenoldopam may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Fenoldopam.
BethanidineBethanidine may increase the hypotensive activities of Fenoldopam.
BimatoprostFenoldopam may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Fenoldopam.
BosentanBosentan may increase the hypotensive activities of Fenoldopam.
BretyliumFenoldopam may increase the hypotensive activities of Bretylium.
BrimonidineFenoldopam may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Fenoldopam.
BupranololFenoldopam may increase the hypotensive activities of Bupranolol.
CandesartanCandesartan may increase the hypotensive activities of Fenoldopam.
CandoxatrilCandoxatril may increase the hypotensive activities of Fenoldopam.
CaptoprilFenoldopam may increase the hypotensive activities of Captopril.
CaroxazoneCaroxazone may increase the hypotensive activities of Fenoldopam.
CarteololCarteolol may increase the hypotensive activities of Fenoldopam.
CarvedilolFenoldopam may increase the hypotensive activities of Carvedilol.
CeliprololFenoldopam may increase the hypotensive activities of Celiprolol.
ChlorothiazideFenoldopam may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Fenoldopam.
CilazaprilFenoldopam may increase the hypotensive activities of Cilazapril.
ClonidineClonidine may increase the hypotensive activities of Fenoldopam.
CryptenamineCryptenamine may increase the hypotensive activities of Fenoldopam.
CyclothiazideCyclothiazide may increase the hypotensive activities of Fenoldopam.
DebrisoquinFenoldopam may increase the hypotensive activities of Debrisoquin.
DeserpidineFenoldopam may increase the hypotensive activities of Deserpidine.
DiazoxideDiazoxide may increase the hypotensive activities of Fenoldopam.
DiltiazemDiltiazem may increase the hypotensive activities of Fenoldopam.
DorzolamideFenoldopam may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Fenoldopam.
EfonidipineFenoldopam may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Fenoldopam.
EnalaprilatFenoldopam may increase the hypotensive activities of Enalaprilat.
EpoprostenolFenoldopam may increase the hypotensive activities of Epoprostenol.
EprosartanFenoldopam may increase the hypotensive activities of Eprosartan.
FelodipineFenoldopam may increase the hypotensive activities of Felodipine.
FosinoprilFosinopril may increase the hypotensive activities of Fenoldopam.
FurazolidoneFurazolidone may increase the hypotensive activities of Fenoldopam.
GuanabenzGuanabenz may increase the hypotensive activities of Fenoldopam.
GuanadrelGuanadrel may increase the hypotensive activities of Fenoldopam.
GuanethidineFenoldopam may increase the hypotensive activities of Guanethidine.
GuanfacineFenoldopam may increase the hypotensive activities of Guanfacine.
HexamethoniumFenoldopam may increase the hypotensive activities of Hexamethonium.
HydracarbazineHydracarbazine may increase the hypotensive activities of Fenoldopam.
HydralazineFenoldopam may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideFenoldopam may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Fenoldopam.
IloprostIloprost may increase the hypotensive activities of Fenoldopam.
IndapamideFenoldopam may increase the hypotensive activities of Indapamide.
IndenololFenoldopam may increase the hypotensive activities of Indenolol.
IndoraminFenoldopam may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Fenoldopam.
IproniazidIproniazid may increase the hypotensive activities of Fenoldopam.
IrbesartanFenoldopam may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Fenoldopam.
IsradipineIsradipine may increase the hypotensive activities of Fenoldopam.
LabetalolLabetalol may increase the hypotensive activities of Fenoldopam.
LacidipineFenoldopam may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Fenoldopam.
LercanidipineLercanidipine may increase the hypotensive activities of Fenoldopam.
LisinoprilLisinopril may increase the hypotensive activities of Fenoldopam.
LofexidineFenoldopam may increase the hypotensive activities of Lofexidine.
LosartanLosartan may increase the hypotensive activities of Fenoldopam.
MacitentanFenoldopam may increase the hypotensive activities of Macitentan.
ManidipineFenoldopam may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Fenoldopam.
MecamylamineMecamylamine may increase the hypotensive activities of Fenoldopam.
MethyldopaFenoldopam may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Fenoldopam.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Fenoldopam.
MetipranololFenoldopam may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Fenoldopam.
MetoprololMetoprolol may increase the hypotensive activities of Fenoldopam.
MibefradilFenoldopam may increase the hypotensive activities of Mibefradil.
MinaprineMinaprine may increase the hypotensive activities of Fenoldopam.
MinoxidilMinoxidil may increase the hypotensive activities of Fenoldopam.
MoclobemideMoclobemide may increase the hypotensive activities of Fenoldopam.
MoexiprilMoexipril may increase the hypotensive activities of Fenoldopam.
MolsidomineMolsidomine may increase the hypotensive activities of Fenoldopam.
MoxonidineFenoldopam may increase the hypotensive activities of Moxonidine.
NadololFenoldopam may increase the hypotensive activities of Nadolol.
NebivololFenoldopam may increase the hypotensive activities of Nebivolol.
NialamideNialamide may increase the hypotensive activities of Fenoldopam.
NicardipineNicardipine may increase the hypotensive activities of Fenoldopam.
NicorandilFenoldopam may increase the hypotensive activities of Nicorandil.
NiguldipineFenoldopam may increase the hypotensive activities of Niguldipine.
NilvadipineFenoldopam may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Fenoldopam.
NisoldipineNisoldipine may increase the hypotensive activities of Fenoldopam.
NitrendipineFenoldopam may increase the hypotensive activities of Nitrendipine.
NitroprussideNitroprusside may increase the hypotensive activities of Fenoldopam.
ObinutuzumabFenoldopam may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Fenoldopam.
OlmesartanOlmesartan may increase the hypotensive activities of Fenoldopam.
OmapatrilatFenoldopam may increase the hypotensive activities of Omapatrilat.
OxprenololFenoldopam may increase the hypotensive activities of Oxprenolol.
PargylineFenoldopam may increase the hypotensive activities of Pargyline.
PenbutololFenoldopam may increase the hypotensive activities of Penbutolol.
PentoliniumFenoldopam may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Fenoldopam.
PerindoprilPerindopril may increase the hypotensive activities of Fenoldopam.
PhenelzinePhenelzine may increase the hypotensive activities of Fenoldopam.
PheniprazinePheniprazine may increase the hypotensive activities of Fenoldopam.
PhenoxybenzamineFenoldopam may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Fenoldopam.
PhentolaminePhentolamine may increase the hypotensive activities of Fenoldopam.
PinacidilFenoldopam may increase the hypotensive activities of Pinacidil.
PindololFenoldopam may increase the hypotensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Fenoldopam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Fenoldopam.
PolythiazideFenoldopam may increase the hypotensive activities of Polythiazide.
PrazosinPrazosin may increase the hypotensive activities of Fenoldopam.
PropranololPropranolol may increase the hypotensive activities of Fenoldopam.
QuinaprilFenoldopam may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Fenoldopam.
RamiprilRamipril may increase the hypotensive activities of Fenoldopam.
RasagilineRasagiline may increase the hypotensive activities of Fenoldopam.
RemikirenRemikiren may increase the hypotensive activities of Fenoldopam.
RescinnamineFenoldopam may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Fenoldopam.
RiociguatFenoldopam may increase the hypotensive activities of Riociguat.
RituximabFenoldopam may increase the hypotensive activities of Rituximab.
SafrazineSafrazine may increase the hypotensive activities of Fenoldopam.
SaprisartanFenoldopam may increase the hypotensive activities of Saprisartan.
SelegilineSelegiline may increase the hypotensive activities of Fenoldopam.
SelexipagFenoldopam may increase the hypotensive activities of Selexipag.
SildenafilSildenafil may increase the antihypertensive activities of Fenoldopam.
SitaxentanFenoldopam may increase the hypotensive activities of Sitaxentan.
SpiraprilFenoldopam may increase the hypotensive activities of Spirapril.
TadalafilTadalafil may increase the antihypertensive activities of Fenoldopam.
TelmisartanFenoldopam may increase the hypotensive activities of Telmisartan.
TemocaprilFenoldopam may increase the hypotensive activities of Temocapril.
TerlipressinFenoldopam may increase the hypotensive activities of Terlipressin.
TiboloneFenoldopam may increase the hypotensive activities of Tibolone.
TicrynafenFenoldopam may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Fenoldopam.
TolazolineTolazoline may increase the hypotensive activities of Fenoldopam.
ToloxatoneToloxatone may increase the hypotensive activities of Fenoldopam.
TorasemideTorasemide may increase the hypotensive activities of Fenoldopam.
TrandolaprilTrandolapril may increase the hypotensive activities of Fenoldopam.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Fenoldopam.
TranylcypromineTranylcypromine may increase the hypotensive activities of Fenoldopam.
TravoprostTravoprost may increase the hypotensive activities of Fenoldopam.
TreprostinilTreprostinil may increase the hypotensive activities of Fenoldopam.
TrichlormethiazideFenoldopam may increase the hypotensive activities of Trichlormethiazide.
TrimazosinFenoldopam may increase the hypotensive activities of Trimazosin.
TrimethaphanFenoldopam may increase the hypotensive activities of Trimethaphan.
UdenafilUdenafil may increase the antihypertensive activities of Fenoldopam.
UnoprostoneFenoldopam may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Fenoldopam.
VardenafilVardenafil may increase the antihypertensive activities of Fenoldopam.
XylometazolineFenoldopam may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Fenoldopam.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Zeng C, Han Y, Huang H, Yu C, Ren H, Shi W, He D, Huang L, Yang C, Wang X, Zhou L, Jose PA: D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression. J Hypertens. 2009 May;27(5):1033-41. doi: 10.1097/HJH.0b013e3283293c7b. [PubMed:19293728 ]
  4. Dhasmana KM, Villalon CM, Zhu YN, Parmar SS: The role of dopamine (D2), alpha and beta-adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine-related drugs in the rat. Pharmacol Res. 1993 May-Jun;27(4):335-47. [PubMed:8103596 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Zeng C, Han Y, Huang H, Yu C, Ren H, Shi W, He D, Huang L, Yang C, Wang X, Zhou L, Jose PA: D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression. J Hypertens. 2009 May;27(5):1033-41. doi: 10.1097/HJH.0b013e3283293c7b. [PubMed:19293728 ]
  3. Dhasmana KM, Villalon CM, Zhu YN, Parmar SS: The role of dopamine (D2), alpha and beta-adrenoceptor receptors in the decrease in gastrointestinal transit induced by dopamine and dopamine-related drugs in the rat. Pharmacol Res. 1993 May-Jun;27(4):335-47. [PubMed:8103596 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Martin SW, Broadley KJ: Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade. Br J Pharmacol. 1995 May;115(2):349-55. [PubMed:7670737 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23